Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Non-Alcoholic Fatty Liver Disease (NAFLD): early-phase trial registry

3 of 10 indexed Non-Alcoholic Fatty Liver Disease (NAFLD) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Non-Alcoholic Fatty Liver Disease (NAFLD): 10 US clinical trials tracked, 3 recruiting.

Non-Alcoholic Fatty Liver Disease (NAFLD) is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Miriam Vos, MD, running 1 of these trials.

Enrollment posture brief

Registry condition non-alcoholic-fatty-liver-disease-nafld

OPEN 3 | RECR 30% | LATE 0 | EARLY 4 | RANK #1724 | SPON 1

Volume-matched condition peers

Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Non-Alcoholic Fatty Live (th…30%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease (NAFLD) lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Non-Alcoholic Fatty Liver Disease (NAFLD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Non-Alcoholic Fatty Liver Disease (NAFLD) is recruiting below its size-band peers.

    3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Non-Alcoholic Fatty Liver Disease (NAFLD) trials is spread across many organizations.

    Miriam Vos, MD accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Non-Alcoholic Fatty Liver Disease (NAFLD) trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Non-Alcoholic Fatty Liver Disease (NAFLD) research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Top Sponsors

Miriam Vos, MD 1 trials
Corcept Therapeutics 1 trials
University Hospitals Cleveland Medical Center 1 trials
Washington University School of Medicine 1 trials
Emory University 1 trials
Brigham and Women's Hospital 1 trials
University of California, Davis 1 trials
Beth Israel Deaconess Medical Center 1 trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1 trials
Massachusetts General Hospital 1 trials

Named interventions

Most-linked intervention names on Non-Alcoholic Fatty Liver Disease (NAFLD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
tesamorelin Drug
1 trials
obeticholic acid Drug
1 trials
IMM-124E Biological
1 trials
oral carbohydrate challenge Dietary supplement
1 trials
Serologic features of NASH Diagnostic test
1 trials
Radiologic features of NASH Diagnostic test
1 trials
Liver Function Test Diagnostic test
1 trials

US sites by state

Facility locations filed on Non-Alcoholic Fatty Liver Disease (NAFLD) trials. A trial with sites in several states counts in each.

Missouri 3 trials
Massachusetts 3 trials
Ohio 2 trials
Georgia 2 trials
California 2 trials
Washington 1 trials
Virginia 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Non-Alcoholic Fatty Liver Disease (NAFLD) page

10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Non-Alcoholic Fatty Liver Disease (NAFLD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Miriam Vos, MD sponsors the most Non-Alcoholic Fatty Liver Disease (NAFLD) trials on record, review their full trial history before evaluating a specific study. See Miriam Vos, MD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Alcoholic Fatty Liver Disease (NAFLD) condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.